Sugi Predict

Sugi Predict / Compounds / SCHEMBL1857673

SCHEMBL1857673

SCHEMBL1857673

NC1CCc2cc(Cl)ccc21

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ SRD5A1 P18405 4/20 0.47
▸ SRD5A2 P31213 2/20 0.45
▸ HTR2C P28335 3/20 0.45
▸ HTR2A P28223 2/20 0.45
▸ HTR2B P41595 2/20 0.45
▸ F10 P00742 1/20 0.43
▸ KDM1A O60341 2/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ AADAT Q8N5Z0 1/20 0.39
▸ FADS1 O60427 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29443577 1.00 SRD5A1 (0.47) SRD5A1SRD5A2HTR2CHTR2AHTR2B
SCHEMBL1859026 1.00 SRD5A1 (0.47) SRD5A1SRD5A2HTR2CHTR2AHTR2B
SCHEMBL29443582 1.00 SRD5A1 (0.47) SRD5A1SRD5A2HTR2CHTR2AHTR2B
SCHEMBL192318 1.00 SRD5A1 (0.47) SRD5A1SRD5A2HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL26664227 0.98 SRD5A1 (0.46) SRD5A1SRD5A2HTR2CHTR2AHTR2B
Hydrochloric Acid SCHEMBL17579539 0.98 SRD5A1 (0.46) SRD5A1SRD5A2HTR2CHTR2AHTR2B
SCHEMBL3535473 0.89 KDM1A (0.45) SRD5A1SRD5A2HTR2CHTR2AHTR2B
SCHEMBL22652225 0.89 KDM1A (0.45) SRD5A1SRD5A2HTR2CHTR2AHTR2B
SCHEMBL1004804 0.86 HTR2C (0.47) HTR2CHTR2AHTR2BKDM1ASLC6A4
SCHEMBL7895243 0.86 HTR2C (0.47) HTR2CHTR2AHTR2BKDM1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099936-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A AbbVie Deutschland GmbH & Co. KG (DE) 2018-04-12 — — US claimed
US-9856220-B2 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2018-01-02 — — US claimed
EP-2780324-B1 HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A ABBVIE DEUTSCHLAND (DE) 2017-05-17 — — EP claimed
US-20160318871-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE INC. 2016-11-03 — — US claimed
CN-105085279-A Preparation of R-5-chloro-1-aminoindane WU LING 2015-11-25 — — CN claimed
CN-105037169-A Method for preparing S-5-chloro-1-aminoindane WU LING 2015-11-11 — — CN claimed
US-20130116229-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE INC. (US) 2013-05-09 — — US claimed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
US-20230399341-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 MERCK SHARP & DOHME LLC (US) 2023-12-14 — — US disclosed
US-20230399341-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 MERCK SHARP & DOHME LLC (US) 2023-12-14 — — US disclosed
US-20230399341-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 MERCK SHARP & DOHME LLC (US) 2023-12-14 — — US disclosed
EP-4272836-A2 CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-11-08 — — EP disclosed
EP-4240363-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 Merck Sharp & Dohme LLC (US) 2023-09-13 — — EP disclosed
WO-2006013210-A2 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-02-09 — — WO disclosed
US-20050043351-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBVIE INC. 2005-02-24 — — US disclosed
WO-2004111009-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2004-12-23 — — WO disclosed
EP-1183238-A1 METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2002-03-06 — — EP disclosed
WO-2000069816-A1 METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2000-11-23 — — WO disclosed
EP-0144235-A2 N6-(1- and 2-benzocycloalkyl) adenosines, pharmaceutical compositions comprising the same and a process for the production thereof WARNER-LAMBERT COMPANY (US) 1985-06-12 — — EP disclosed
US-4096173-A Chlorinated 1-aminoindane N-methyl transferase inhibitors ELI LILLY AND COMPANY (US) 1978-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318871-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE3A, PDE5A, PDE3B SRD5A1 98/4885SRD5A2 196/4885HTR2C 86/4885
US-20130116229-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE7A, PDE5A, PDE2A SRD5A1 524/4885SRD5A2 943/4885HTR2C 610/4885
US-20230399341-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 PHKG1, PDXK, HIPK1 SRD5A1 1642/4885SRD5A2 2164/4885HTR2C 3689/4885
US-20180099936-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE3A, PDE5A, PDE3B SRD5A1 100/4885SRD5A2 198/4885HTR2C 88/4885
US-20050043351-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ARRB1, TRPV1, TRPV5 SRD5A1 475/4885SRD5A2 909/4885HTR2C 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.